These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33994737)

  • 21. Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
    Sereti E; Papapostolou I; Dimas K
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects.
    Polani F; Grierson PM; Lim KH
    World J Gastroenterol; 2021 May; 27(18):2105-2121. PubMed ID: 34025067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic Therapeutic Strategies to Target Molecular and Cellular Heterogeneity in Pancreatic Cancer.
    Versemann L; Hessmann E; Ulisse M
    Visc Med; 2022 Feb; 38(1):11-19. PubMed ID: 35291698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer.
    Ware MB; El-Rayes BF; Lesinski GB
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
    Gleeson FC; Levy MJ
    Curr Treat Options Gastroenterol; 2018 Dec; 16(4):441-448. PubMed ID: 30178242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel.
    Brouwer TP; Vahrmeijer AL; de Miranda NFCC
    Cell Oncol (Dordr); 2021 Apr; 44(2):261-278. PubMed ID: 33710604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of pancreatic cancer.
    Sunami Y; Kleeff J
    Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
    Sereti E; Karagianellou T; Kotsoni I; Magouliotis D; Kamposioras K; Ulukaya E; Sakellaridis N; Zacharoulis D; Dimas K
    J Proteomics; 2018 Sep; 188():107-118. PubMed ID: 29398619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-derived preclinical models to develop immunotherapies.
    Seoane J
    Mol Oncol; 2023 Jul; 17(7):1169-1172. PubMed ID: 37278114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving trends in pancreatic cancer therapeutic development.
    Bijou I; Wang J
    Ann Pancreat Cancer; 2019 Oct; 2():. PubMed ID: 33089149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
    Herting CJ; Karpovsky I; Lesinski GB
    Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
    Pham TND; Shields MA; Spaulding C; Principe DR; Li B; Underwood PW; Trevino JG; Bentrem DJ; Munshi HG
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncovering key targets of success for immunotherapy in pancreatic cancer.
    Pretta A; Lai E; Persano M; Donisi C; Pinna G; Cimbro E; Parrino A; Spanu D; Mariani S; Liscia N; Dubois M; Migliari M; Impera V; Saba G; Pusceddu V; Puzzoni M; Ziranu P; Scartozzi M
    Expert Opin Ther Targets; 2021 Nov; 25(11):987-1005. PubMed ID: 34806517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma.
    Roy S; Singh AP; Gupta D
    Heliyon; 2021 Jan; 7(1):e06000. PubMed ID: 33521362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
    Paliard X; Rixe O
    Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.